Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1572531 | 0.85 | LMNA (0.37) | CHRNB2CHRNA7CHRNA4CHRNA5CYP3A4 | |
| SCHEMBL3486781 | 0.77 | KCNN4 (0.41) | CYP3A4SMN1; SMN2MEN1GMNNLMNA | |
| SCHEMBL1873621 | 0.70 | HDAC8 (0.53) | CHRNB2CHRNA7CHRNA4CHRNA5CHRM3 | |
| SCHEMBL1665120 | 0.70 | HDAC8 (0.53) | CHRNB2CHRNA7CHRNA4CHRNA5CHRM3 | |
| SCHEMBL14350218 | 0.70 | CHRNB2 (0.38) | CHRNB2CHRNA7CHRNA4CHRNA5CHRM3 | |
| SCHEMBL9015291 | 0.67 | MEN1 (0.46) | CYP3A4MEN1LMNAKMT2ACHRM3 | |
| SCHEMBL7839730 | 0.67 | MEN1 (0.46) | CYP3A4MEN1LMNAKMT2ACHRM3 | |
| SCHEMBL7448432 | 0.67 | OPRD1 (0.56) | KDM4E | |
| SCHEMBL1873957 | 0.66 | CHRNB2 (0.64) | CHRNB2CHRNA7CHRNA4CHRNA5CHRM3 | |
| SCHEMBL1878139 | 0.66 | CHRNB2 (0.64) | CHRNB2CHRNA7CHRNA4CHRNA5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS INCORPORATED | 2021-05-06 | — | — | US | claimed |
| US-20160067264-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | UNIVERSITY OF SHEFFIELD (GB) | 2016-03-10 | — | — | US | claimed |
| US-20140170768-A1 | METHOD FOR MONITORING AND ASSESSING PITUITARY FUNCTION | I-CALQ LLC | 2014-06-19 | — | — | US | claimed |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2014-01-02 | — | — | US | claimed |
| EP-2532350-A1 | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome | Laboratoire HRA Pharma (FR) | 2012-12-12 | — | — | EP | claimed |
| US-20110224179-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | UNIVERSITY OF SHEFFIELD (GB) | 2011-09-15 | — | — | US | claimed |
| EP-2364146-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | The University Of Sheffield (GB) | 2011-09-14 | — | — | EP | claimed |
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CORCEPT THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2306830-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Corcept Therapeutics, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2010-10-14 | — | — | US | claimed |
| WO-2009050136-A2 | GLUCOCORTICOID RECEPTOR ANTAGONISTS SUCH AS MIFEPRISTONE FOR TREATING CUSHING' S SYNDROME | LABORATOIRE HRA PHARMA (FR) | 2009-04-23 | — | — | WO | claimed |
| EP-2012796-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | Corcept Therapeutics, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007131041-A2 | THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2 | CORCEPT THERAPEUTICS, INC. (US) | 2007-11-15 | — | — | WO | claimed |
| US-20020065259-A1 | Glucocorticoid blocking agents for increasing blood-brain barrier permeability | BIOPHARMA SECURED DEBT FUND II SUB, S.AR.L (LU) | 2002-05-30 | — | — | US | claimed |
| WO-2002040018-A1 | TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON, INC. (CH) | 2002-05-23 | — | — | WO | claimed |
| WO-2002017930-A2 | GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD-BRAIN BARRIER PERMEABILITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-03-07 | — | — | WO | claimed |
| US-6177427-B1 | NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. | 2001-01-23 | — | — | US | claimed |
| EP-1047410-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 2000-11-02 | — | — | EP | claimed |
| US-6051573-A | Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists | ALCON LABORATORIES, INC. (US) | 2000-04-18 | — | — | US | claimed |
| WO-1999032101-A1 | TREATMENT OF GLC1A GLAUCOMA WITH NON-STEROIDAL GLUCOCORTICOID ANTAGONISTS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261693-A1 | METHOD FOR TREATING CUSHING'S SYNDROME | MC2R, CRH, CRHR2 | CHRNB2 677/4885CHRNA7 526/4885CHRNA4 1071/4885 |
| US-20110166115-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | CHRNB2 790/4885CHRNA7 780/4885CHRNA4 552/4885 |
| US-20110224179-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | CRH, SHBG, MC2R | CHRNB2 552/4885CHRNA7 908/4885CHRNA4 849/4885 |
| US-20160067264-A1 | MEDICAMENT AND METHOD OF DIAGNOSIS | CRH, SHBG, MC2R | CHRNB2 631/4885CHRNA7 948/4885CHRNA4 945/4885 |
| US-20140005158-A1 | USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CRHR1, NR3C1, CRH | CHRNB2 790/4885CHRNA7 780/4885CHRNA4 552/4885 |
| US-20210128584-A1 | USE OF GLUCOCORTICOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NR3C1, CRHR1, NR3C2 | CHRNB2 169/4885CHRNA7 234/4885CHRNA4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.